Login
Dexcom NASDAQ: DXCM
Dexcom, Inc. is a company that develops, manufactures and distributes continuous glucose monitoring systems for diabetes management
| Name | Dexcom |
| Ticker | DXCM |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
| Price | 354.20 |
| 52W Low/High | 191.16 / 451.79 |
| Market cap | 34 B |
| 1Y Total Return |
53.47%
Strong |
| 1Y Volatility |
56.11%
Average Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Dexcom, Inc. is a company that develops, manufactures and distributes continuous glucose monitoring systems for diabetes management
Details
| Ticker | DXCM |
| Name | Dexcom |
| ISIN | US2521311074 |
| CUSIP | 252131107 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 1/15/21
| Close Price | 354.20 |
| 52W Low/High | 191.16 / 451.79 |
| Market cap | 34 B |
| 1Y Total Return |
53.47%
Strong |
| 1Y Volatility |
56.11%
Average Risk |
| Beta | 1.57 |
| PE (trailing) |
145.76
High |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 12.7% |
| Cash from Op. / Cur. Liabilities | 0.88 |
| Diluted Earnings / Share | 2.43 |
| ROE | 20.4% |
| ROIC | 15.8% |
| Price / Revenue | 19.4 |
| Price / Book | 23.5 |
| Price / CF | 78.8 |
| Current Ratio | 6.4 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 1.18 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
1,821
|
1,351
|
915
|
669
|
533
|
356
|
|
| Gross Profit |
1,190
|
845
|
595
|
455
|
353
|
247
|
|
| R&D |
320
|
252
|
191
|
180
|
141
|
131
|
|
| EBITDA |
374
|
-71
|
102
|
-40
|
-41
|
-47
|
|
| Operating Income |
297
|
-124
|
-10
|
-61
|
-56
|
-57
|
|
| Net Income exc. Extra |
231
|
-
|
43
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
100
|
93
|
90
|
87
|
84
|
81
|
|
| EPS exc. Extra |
2.43
|
-1.95
|
0.47
|
-0.56
|
-0.66
|
-0.72
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
3,833
|
2,186
|
1,114
|
843
|
362
|
257
|
|
| Cash, Eq & Invt ShortTerm |
2,604
|
1,430
|
669
|
526
|
127
|
113
|
|
| Total Current Assets |
3,237
|
1,816
|
914
|
693
|
259
|
204
|
|
| Total Non-Current Assets |
596
|
370
|
200
|
150
|
103
|
53
|
|
| Intangibles |
19
|
18
|
18
|
12
|
13
|
6
|
|
| Total Liabilities |
2,334
|
1,421
|
552
|
459
|
100
|
63
|
|
| Total Current Liabilities |
506
|
322
|
194
|
118
|
86
|
59
|
|
| Long Term Debt |
1,828
|
1,099
|
358
|
341
|
14
|
5
|
|
| Shareholder equity |
1,499
|
764
|
562
|
384
|
262
|
193
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
447
|
205
|
131
|
64
|
54
|
46
|
|
| Depreciation |
61
|
43
|
25
|
16
|
15
|
10
|
|
| Cash from Investing |
-1,088
|
-890
|
-172
|
-161
|
-51
|
-44
|
|
| Capex |
183
|
154
|
67
|
66
|
50
|
26
|
|
| Cash from Financing |
917
|
712
|
9
|
400
|
10
|
20
|
|
| Stock Issued |
15
|
96
|
11
|
11
|
13
|
22
|
|
| Debt (LT) Issued |
906
|
618
|
0
|
391
|
-3
|
-2
|
|
| Free Cash Flow |
79
|
-305
|
10
|
-118
|
-135
|
-122
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
12.7%
|
-
|
4.7%
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
150.6%
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
6.4
|
5.6
|
4.7
|
5.9
|
3.0
|
3.5
|
|
| Financial Leverage D/E |
1.18
|
1.43
|
0.60
|
0.84
|
0.00
|
0.02
|
|
| Return on Capital Avg |
15.8%
|
-10.4%
|
22.1%
|
-15.9%
|
-38.7%
|
-68.6%
|
|
| Return on Shareholder Equity |
20.4%
|
-
|
9.1%
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available